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Angiotensin-converting enzyme (ACE) inhibitors are the leading cause of a drug-induced angioedema. This occurrence is
frequently underdiagnosed, but its relapse can be life-threatening. The authors’ intention in reporting this clinical case is to sound
a warning about reviewing attitudes and surveillance to try to improve patient perioperative safety.
1. Introduction
Angiotensin-converting enzyme (ACE) inhibitors are widely
prescribed and are the leading cause of a drug-induced angi-
oedema [1]. However, contrary to what may happen with
other drugs, this adverse reaction is frequently missed
because it can start years after beginning the treatment and
recurs erratically but with increased morbidity severity or
even mortality [2].
The management of these severe adverse reactions has
been discussed but still missing consensus about periopera-
tive surveillance guidelines in patients taking ACE inhibitors
[3–6].However, it is obviously unquestionable that the quality
of perioperative care is crucial to the patient’s safety, and all
medical surveillance decisions must be carefully planned and
implemented.
The severity of this case legitimizes it being reported to
raise the awareness of health care professionals and propose
preventive attitudes for discussion that could improve the
perioperative safety of patients.
The patient reviewed the case report and gave permission
for the authors to publish.
2. Case Description
We report the case of amale Caucasian, 81-year-old, weighing
90 kg, and 175 cm tall. He was hospitalized in the Burn
Intensive Care Unit (BICU) with a third-degree burn of the
foot and he was proposed for surgical cleaning with skin
grafting. The patient was conscious and oriented but with
amnesia regarding his medical history. The anesthetic risk by
the American Society of Anesthesiologists classification was
grade III due to hypertension, and he hadNYHAclass II heart
failure. The usual pharmacological therapy was perindopril,
furosemide, finasteride, and pantoprazole.
We performed a combined anesthesia: femoral/sciatic
nerve blocks with ropivacaine associated to general anes-
thesia with propofol, fentanyl, and sevoflurane. For airway
patency, we used a nontraumatic supraglottic device (Igel),
and the patient was in spontaneous ventilation all the time.
There were no abnormal or unexpected incidents during the
operation. The overall perioperative period was spent in the
BICU with constant medical surveillance.
Five hours later, the patient developed dysphagia and
mild respiratory distress. He was aware and oriented but anx-
ious with polypnea and tachycardia. The main clinical sign
was oropharyngeal edema involving the tongue (Figure 1).
The upper airways were nebulized with epinephrine.
Intravenous drugs were given: 250mg methylprednisolone
and 2mg clemastine. We opted to keep the patient under
strict medical surveillance without additional specific drug
therapy but keeping a possible emergency tracheostomy in
mind.The daily therapy was reviewed, and the ACE inhibitor,
perindopril, was suspended. Laboratory blood levels of IgE
and tryptase were normal.
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Figure 1: Oropharyngeal edema involving the tongue.
Figure 2: After 24 hours of ACE inhibitor suspension.
After 24 hours of ACE inhibitor suspension there was a
clinical improvement (Figure 2).There were no new episodes
in the six-month follow-up period.
3. Discussion
ACE inhibitors are the most common cause of nonhereditary
angioedema (25–39%). The probability that a patient taking
an ACE inhibitor will go on to develop angioedema is 0.1–
0.7% [7–9]. However and unlike other cases of drug-related
angioedema, this adverse reaction is frequently missed
because it can start years after beginning the treatment and
recurs erratically while treatment continues. Another clinical
concern is that the severity of adverse reactions increases with
each recurrence and can be life-threatening [10–13].
The bradykinin receptor and its active metabolites have
been demonstrated experimentally as humoral mechanisms
of angioedema due to increased levels of nitric oxide, prosta-
cyclin PG12, and neuropeptide substance P and a consequent
increase in vascular permeability. The inactivation of kinins
is mainly caused by angiotensin-converting enzyme (ACE),
but other important enzymes are aminopeptidase (APP),
dipeptidyl peptidase IV (DPP-IV), and neutral endopepti-
dase (NEP) [3].
Patients taking other drugs that are also bradykinin-
degrading enzyme inhibitors are at increased risk. Diabetic
patients have new drug therapies that are DPP-IV inhibitors
(sitagliptin, saxagliptin, and vildagliptin). Transplant recip-
ients with immunosuppressant medications should receive
inhibition of DPP-IV enzyme activity to improve graft sur-
vival success [3].
In addition to the amount of bradykinin, individual sen-
sitivity is an important factor to trigger angioedema. In the
presence of clinical angioedema, we should exclude heredi-
tary autosomal dominant disease typified by a deficiency or
dysfunction of the C1-esterase inhibitor [14].
Perioperative patients taking ACE inhibitors have mainly
been studied in relation to anesthetic hemodynamic stability
[15, 16]. The possibility of severe angioedema must be dis-
cussed enough for the best practices improvement [17].
In perioperative medicine, preventive attitudes begin
with preoperative evaluation, anesthetic-surgery planning,
and appropriate postoperative recovery care [18]. These
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surveillance attitudes do not necessarily mean more medical
care but are essential for a better health care.
In the case reported here, the first main concern was the
hypothesis of an anaphylactic reaction to surgical/anesthetic
procedures and the inherent therapy. However, the painless,
nonpruritic mucosal edema was restricted to the oral cavity
localized, with only slight response to the antianaphylactic
drugs, and the blood tests were normal. The only drug dis-
continued was the ACE inhibitor, while the other drugs were
administered daily, and there was a late but sustained clin-
ical improvement without further episodes in the following
months. We conclude that the patient had a severe life-
threatening angioedema with high probability that the eti-
ology was directly related to the previous treatment with an
ACE inhibitor [7].
There are risk factors for oral angioedema that should be
evaluated in patients taking ACE inhibitors: older age, femal
sex, Hispanic race, or African-American ancestry. Also,
patients should be screened for positive smoking history,
coexistent cardiopulmonary disease, class III or above of
Anesthesiologist’s American Society, previous allergic reac-
tions, and cough or taking other drugs that are also
bradykinin-degrading enzyme inhibitors [19, 20].
This patient had several risk factors for severe angio-
edema: the therapy with ACE inhibitor which was not
stopped, older age, Hispanic race, class III of Anesthesiol-
ogist’s American Society, and coexistent cardiopulmonary
disease.
The patient’s therapy with ACE inhibitor, perindopril,
was not stopped before surgery because the patient had no
previous adverse reactions, and postoperatively he will stay
in Burn Intensive Care Unit under safety vigilance. The ACE
inhibitors intake suspension or replacement remains a
dilemma. Researchers of Toronto General Hospital reviewed
data from more than 61,000 perioperative patients and
concluded that therapy with ACE inhibitors does not have
additional morbidity or mortality. Although this evidence is
encouraging, randomized prospective confirmatory trials
must confirm that conclusion [21]. The American College of
Physicians issued recommendations on the perioperative
management of patients stating that clinicians should con-
sider holding or reducing the usual dose of ACE inhibitors for
better perioperative patient’s hemodynamic stability [22, 23].
In the absence of adverse reactions, drug discontinuations
have to be carefully planned and weighted [24, 25]. If patients
have been recommended to discontinue ACE inhibitor and
replace it, upon advice of a physician, such exchange should
take place as early as possible.However, some studies revealed
that patients are still at risk of developing angioedema during
several months after therapeutic stop [26]. The patients
with adverse reactions to ACE inhibitors can have safer
alternatives with angiotensin II receptor blockers (ARBs) or
calcium channel blockers [27, 28]. Although, there are
reports that 10% of patients with previous ACE inhibitors
angioedema also develop this adverse reaction after changing
the medication to ARBs [29, 30].
The anesthetic airway manipulations are an additional
risk factor for oropharyngeal edema. Although trauma may
trigger angioedema, the intensity and time to onset are
not clear [31]. This patient had a nontraumatic supraglottic
device (Igel); however we cannot exclude this etiology for
angioedema trigger. Whenever possible, avoiding airway
manipulating should be one of the angioedema preventive
anesthetic attitudes for patients taking ACE inhibitor.
The postoperative vigilance is the main key for the
anesthetic plan and safety of these patients. The oral edema
severity of this case occurred five hours after the operation.
Fortunately, the patient was under medical supervision in a
specialized intensive care unit.Therefore, patients with recent
ACE inhibitor intake should have postoperative surveillance
suited to their conscientious autonomy and accessibility to
emergency care units.
Our report raises the awareness of health care profession-
als for preventive attitudes. Probably in the near future the
pharmacogenomics and personalized medicine applications
can improve patient safety and prevent morbidity [32, 33].
4. Conclusions
Perioperative ACE inhibitor angioedema is a rare occurrence
but can be life-threatening. Unfortunately, there is no specific
test that can predict that adverse reaction. ACE inhibitor
intake withdrawn is themain treatment and the only prophy-
lactic measure to avoid the drug-induced angioedema.
Preoperative risk stratification aims to determine prob-
abilities, optimize medical therapy, and modify risk factors.
Before the surgery, patients with increased risk factors for
severe cases of angioedema should withdraw ACE inhibitor
as early as possible.
After theACE inhibitors withdraw, the probability of ang-
ioedema lowers with the passing time. However the occur-
rence of angioedema should always be adequately surveyed.
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